CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

Gadelmawla AF, Hammad N, Atta K, Diaa A, Abouzkaly F, Soni K, Kelkar R, Agrawal SP, Ahmed R, Jain H, Passey S, Aronow WS

The American journal of cardiology26 Feb 2026

PMID41759565DOI10.1016/j.amjcard.2026.02.030PepBankPUB-41759565

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in patients with obesity, CagriSema produced greater percent weight loss than semaglutide or placebo (Cohen's d -1.38).
In plain wordsIn people with obesity, CagriSema led to more percent weight loss than semaglutide or placebo in pooled trials.
Peptide
Cagrilintide
Outcome
DecreasePercent change in body weight
Study
n = 4,419
Comparator
Semaglutide or placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Cohen's d
−1.38 SD
percent weight loss
Source sentences
Summary
Pooled analysis showed that CagriSema significantly reduced percent weight loss (Cohen's d: -1.38; 95% CI: -1.84 to -0.91; I² = 94.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4175956501
02HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in patients with obesity, CagriSema gave greater absolute weight loss than semaglutide or placebo.
In plain wordsIn people with obesity, CagriSema led to more weight loss in kilograms than semaglutide or placebo in pooled trials.
Peptide
Cagrilintide
Outcome
DecreaseAbsolute weight loss
Study
n = 4,419
Comparator
Semaglutide or placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference, absolute weight loss
−11 kg
CagriSema vs control
Source sentences
Summary
CagriSema also resulted in greater absolute weight loss (MD: -11 kg)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4175956502
03HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in patients with obesity, CagriSema reduced waist circumference more than semaglutide or placebo.
In plain wordsIn people with obesity, CagriSema reduced waist size more than semaglutide or placebo in pooled trials.
Peptide
Cagrilintide
Outcome
DecreaseWaist circumference
Study
n = 4,419
Comparator
Semaglutide or placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference, waist circumference
−9.41 cm
CagriSema vs control
Source sentences
Summary
waist circumference (MD: -9.41 cm)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4175956503
04HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in patients with obesity, CagriSema lowered systolic blood pressure more than semaglutide or placebo.
In plain wordsIn people with obesity, CagriSema lowered systolic blood pressure more than semaglutide or placebo in pooled trials.
Peptide
Cagrilintide
Outcome
DecreaseSystolic blood pressure
Study
n = 4,419
Comparator
Semaglutide or placebo
Outcome group
Blood pressure · Cardiovascular
Measurements
Mean difference, systolic blood pressure
−7.06 mmHg
CagriSema vs control
Source sentences
Summary
systolic blood pressure (MD: -7.06 mmHg)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4175956504
05HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome
In a meta-analysis of randomised trials in patients with obesity, gastrointestinal adverse events were more frequent with CagriSema than with semaglutide or placebo.
In plain wordsIn people with obesity, CagriSema caused more stomach and bowel side effects than semaglutide or placebo.
Peptide
Cagrilintide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 4,419
Comparator
Semaglutide or placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Risk ratio
1.32 ratio
gastrointestinal adverse events
Source sentences
Summary
Gastrointestinal adverse events were more frequent (RR: 1.32).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4175956505
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) gave greater percent weight loss than pooled semaglutide monotherapy or placebo.
In plain wordsIn adults with obesity, the CagriSema combination gave more weight loss than semaglutide alone or placebo pooled together.
Peptide
Semaglutide
Outcome
DecreasePercent weight loss
Study
n = 4,419
Comparator
Semaglutide monotherapy or placebo (pooled)
Outcome group
Body weight · Metabolic and weight
Measurements
Cohen's d
−1.38 SD
percent weight loss
Source sentences
Summary
Pooled analysis showed that CagriSema significantly reduced percent weight loss (Cohen's d: -1.38; 95% CI: -1.84 to -0.91; I² = 94.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4175956506
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) gave greater absolute weight loss than pooled semaglutide monotherapy or placebo.
In plain wordsIn adults with obesity, the CagriSema combination gave more weight loss in kilograms than semaglutide alone or placebo pooled together.
Peptide
Semaglutide
Outcome
DecreaseAbsolute weight loss
Study
n = 4,419
Comparator
Semaglutide monotherapy or placebo (pooled)
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−11 kg
absolute weight loss
Source sentences
Summary
CagriSema also resulted in greater absolute weight loss (MD: -11 kg), waist circumference (MD: -9.41 cm), and systolic blood pressure (MD: -7.06 mmHg).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4175956507
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) reduced waist circumference more than pooled semaglutide monotherapy or placebo.
In plain wordsIn adults with obesity, the CagriSema combination reduced waist size more than semaglutide alone or placebo pooled together.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference
Study
n = 4,419
Comparator
Semaglutide monotherapy or placebo (pooled)
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−9.41 cm
waist circumference
Source sentences
Summary
CagriSema also resulted in greater absolute weight loss (MD: -11 kg), waist circumference (MD: -9.41 cm), and systolic blood pressure (MD: -7.06 mmHg).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4175956508
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) lowered systolic blood pressure more than pooled semaglutide monotherapy or placebo.
In plain wordsIn adults with obesity, the CagriSema combination lowered systolic blood pressure more than semaglutide alone or placebo pooled together.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure
Study
n = 4,419
Comparator
Semaglutide monotherapy or placebo (pooled)
Outcome group
Blood pressure · Cardiovascular
Measurements
Mean difference
−7.06 mmHg
systolic blood pressure
Source sentences
Summary
CagriSema also resulted in greater absolute weight loss (MD: -11 kg), waist circumference (MD: -9.41 cm), and systolic blood pressure (MD: -7.06 mmHg).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4175956509
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity, gastrointestinal adverse events were more frequent with CagriSema (semaglutide plus cagrilintide) than with pooled semaglutide monotherapy or placebo.
In plain wordsIn adults with obesity, stomach and gut side effects were more common with the CagriSema combination than with semaglutide alone or placebo pooled together.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 4,419
Comparator
Semaglutide monotherapy or placebo (pooled)
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Risk ratio
1.32 RR
gastrointestinal adverse events
Source sentences
Summary
Gastrointestinal adverse events were more frequent (RR: 1.32).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched MEDLINE (via PubMed), Web of Science, Scopus, and Cochrane Library, from inception to July 2025, for randomized controlled trials (RCTs) comparing CagriSema with semaglutide monotherapy or placebo in patients with obesity.
Summary · context
Four RCTs (n = 4,419) were included (CagriSema: 3,055; control: 1,364).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4175956510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

Summary

Results from this study10

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords